- Home
- STG vs GRML Comparison
STG vs GRML Comparison
Compare STG & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STG | GRML |
|---|---|---|
| Founded | 2003 | N/A |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 51.5M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | STG | GRML |
|---|---|---|
| Price | $3.15 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 467.1K | ★ 3.6M |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $0.27 |
| 52 Week High | $15.00 | $0.55 |
Technical Indicators
Market Signals| Indicator | STG | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 31.38 |
| Support Level | $3.03 | $0.27 |
| Resistance Level | $3.62 | $0.44 |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.08 | 11.11 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.